GLP-1 side effects timeline.

The most common question people ask in their first weeks on a GLP-1, after the logistics of injecting a pen into their own thigh have stopped feeling strange, is some version of: is this normal? The nausea that arrived 36 hours after the dose bump. The afternoon fatigue that landed in week 3 and refuses to leave. The scale that stopped moving at month 3, right as a wad of hair came out of the brush.

This article is an attempt to answer that question by stepping back from individual symptoms and looking at the timeline. In trial data, GLP-1 side effects move on a roughly predictable curve tied to dose escalation. Nausea peaks at specific weeks. Fatigue has a known intensity window. Hair loss shows up on a delay. The "3-month stall" everyone talks about online has a different shape than the real pharmacological plateau in the trials.

What follows is not a triage tool, and it is not a personal prediction. Trial populations report patterns; individual people experience their own version of those patterns at their own pace. The article describes what is common, when, and which patterns are worth bringing to the team that prescribed the medication. Everything that needs a clinical answer still needs one.

How GLP-1 dose escalation shapes the side-effect curve.

Both semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are titrated in steps. Semaglutide for weight loss goes 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, with four weeks at each dose. Tirzepatide goes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, also stepping every four weeks. The FDA-approved titration schedule is built to give the gut time to adapt before therapeutic doses begin.

That schedule is the reason the side-effect timeline looks the way it does. In the pooled trial data, gastrointestinal events cluster around dose changes: a wave begins a few days after the bump, runs for several days, and then settles before the next step. The starter dose is sub-therapeutic by design. It is for tolerability, not for weight loss. Feeling almost nothing in the first week is normal and is not a sign the drug is not working.

In trial-pooled data, nausea reaches its highest population-level prevalence at around week 20, right at the end of the standard five-step titration, and steadily declines afterward.

The table below is the high-altitude view. Each column is a phase of the journey, each row a side effect, each cell what trial and pharmacovigilance data say tends to be happening at that point. The phase-by-phase notes that follow add the texture.

Week 1, starter dose.

The first week sits on the lowest dose of the schedule: 0.25 mg semaglutide or 2.5 mg tirzepatide. For most people, this dose produces very little. That is the design. The starter dose exists to let the gut adapt before any weight-loss-relevant dose begins, and most trial participants reported only mild symptoms or none at all during this phase.

What does show up for some, in roughly descending frequency:

• A small fraction of "fast responders" notice food noise quieting within 24 to 72 hours. For most people the effect is not yet noticeable.
• Mild nausea or sulfur burps in a minority, peaking a few days after the injection and resolving within the week.
• First-injection injection site reactions: a small bruise, lump, or patch of redness. Most clear inside 24 hours to a few days.

The strongest reassurance for this phase is the inverse of the usual fear. Feeling nothing in week 1 is the modal experience, not a failure of the medication. The starter dose is for tolerability, not for outcomes.

Weeks 2-4, first titration.

The first dose bump (0.5 mg semaglutide or 5 mg tirzepatide) is when many people meet "their" side-effect profile for the first time. Trial data shows GI events cluster around dose changes: nausea typically appears 24 to 72 hours after the bump and lasts roughly three to seven days at that dose level. Each subsequent step tends to produce a fresh, usually smaller wave.

Fatigue begins emerging for many in this window. The first four to eight weeks of treatment are the most intense window for energy loss, driven by some combination of caloric deficit, dehydration from GI losses, and reduced carbohydrate intake. In pooled Wegovy trial data, about 11% of semaglutide patients reported fatigue versus about 5% on placebo, with the heaviest reporting in this early phase.

Constipation behaves differently from nausea. It does not arrive in dose-step waves; it accumulates as gastric emptying stays slowed and food and fluid intake stays low. About 24% of semaglutide 2.4 mg patients reported constipation in the Wharton GI tolerability data versus 11% on placebo. For many, it does not auto-resolve the way nausea does.

Month 2, second titration.

By month 2 (1.0 mg semaglutide or 7.5 mg tirzepatide for those on standard escalation), tolerance is building for nausea. Episodes are shorter, less intense, and more predictable. The cycling pattern continues at each step, but the amplitude drops for most people.

Food aversions are clearer now. Greasy food, sweets, alcohol, and sometimes coffee or red meat become noticeably unappealing. In a 2024 Nature International Journal of Obesity analysis, about 85% of GLP-1 users reported notable preference changes at some point, and 21 to 23% reported shifts in sweet or salty taste perception specifically.

Constipation is often the dominant persistent symptom by month 2. Fatigue is still active for many but tends to ease as eating patterns adapt to the lower appetite. This is also the typical window where people start asking the prescriber whether they should slow titration. That conversation belongs in the clinic.

Months 3-4, around maintenance.

Two new things tend to show up in this window, and both arrive late enough that they catch people off guard.

The hair-shedding window.

Telogen effluvium runs on a delay. The trigger, rapid weight loss, happens in months 1 through 3. The hair does not enter shed phase until roughly weeks 12 to 16. Peak shedding then lasts six to twelve weeks. In the Wegovy trial data, alopecia was reported at 5.3% in participants with more than 20% weight loss versus 2.5% in those with less than 20% loss.

The shedding is not a sign that the drug is harming hair follicles. It is the classic post-trigger TE pattern also seen after childbirth, severe illness, and bariatric surgery. Most people who shed regrow. The regrowth window typically begins around six months after the shedding starts, with full density returning at nine to twelve months.

The "3 to 4 month stall."

The scale stops moving. This is the most-discussed pattern in the online community, and it is real, but it is usually misunderstood. Community-reported stalls at month 3 or 4 typically last two to eight weeks and often coincide with the last titration step. The mechanism is metabolic adaptation, not drug failure.

The trial-level plateau in STEP 1 did not appear until around week 60. STEP 5 and SELECT confirmed sustained loss out to two and four years on continued therapy. What feels like a wall at month 3 is almost always a normal flat stretch inside a longer downward curve.

Mood changes are also worth watching here. In January 2026, the FDA asked manufacturers to remove the suicidal-ideation warning from GLP-1 labels following a 91-trial meta-analysis of 107,910 participants that found no signal of increased risk. That removal is the regulator's read of the population data. Individual monitoring is still recommended, especially for people on antidepressants or benzodiazepines, and persistent low mood, new emotional flatness, or new mental health changes are worth bringing up with the prescribing team.

Months 5-6, settled.

For most people who reach maintenance, the acute GI phase is behind them. Nausea is attenuated or resolved. The titration ladder is finished. The food-noise effect is stable. The food aversions are settled. What is still in play:

• Constipation is often the lingering symptom. At maintenance it tends to be more behavioral than pharmacological: fiber, hydration, and movement do more than they did at month 1.
• Hair shedding is often still active into month 6 for those whose shed began at month 4. Regrowth typically becomes visible around six months after the shed started.
• Lean mass signals become measurable for some. On average across DEXA studies, roughly a third to 40% of total weight lost is lean mass.
• Stalls continue to come and go. The body's metabolic adaptation does not run on a clean schedule, and 2 to 8 week stretches of no scale movement are part of the trial-population pattern, not a deviation from it.

The lean mass picture has a longer arc than the first six months show. The SEMALEAN study tracked DEXA outcomes across twelve months and found that lean mass declined most steeply early, dropped roughly 3 kg by month 7, and then stabilized by month 12 while fat loss continued. Handgrip strength improved by an average of 4.5 kg, and the proportion of participants meeting sarcopenic obesity criteria fell from 49% to 33%. The early lean-mass dip is real; the twelve-month picture is more reassuring than the six-month picture alone suggests, especially in combination with adequate protein intake and resistance training.

Most of what scared people in months 1 and 2 is, by month 6, either resolved or running on a tail that is shorter than the original wave. What is left is usually manageable with sleep, protein, fiber, hydration, and resistance training, and the things that are not manageable that way are the things to bring to the prescribing team.

When to call the prescriber.

The patterns above are descriptions of trial-population data, not personal forecasts. A handful of symptoms sit outside the normal pattern and are the kind of thing the team prescribing the medication should hear about, regardless of where in the timeline they appear.

Nothing in this article tells anyone whether to keep taking, stop taking, or adjust a medication. Those decisions belong with the clinical team. The point of the table is that several patterns sit outside the normal timeline, and being explicit about which ones is more useful than a vague "talk to your doctor" at the end.

What helps across the whole timeline.

Across the trial literature and the post-market reports, the same handful of behaviors keep showing up as things that make the timeline more tolerable. None of them are medication, none of them are brand-specific, and none of them replace a clinical conversation.

• Hydration with electrolytes, particularly during the dose-step weeks when GI losses are highest and thirst drive is lowest.
• Fiber and gentle movement for constipation, which tends to outlast nausea and respond to behavior more than to time.
• Protein at every meal and resistance training as the standard mitigation for the lean-mass signal that SEMALEAN documented.
• Smaller, slower meals to work with the delayed gastric emptying instead of against it.
• Sleep as the under-discussed lever for the fatigue window, which sits on a caloric deficit that is hard to compensate for without rest.

The depth on each of these belongs in its own article. The point in this one is that the side-effect timeline is not just a clock to be endured. It is a window in which a small set of behaviors compound, and those behaviors are the same ones that protect outcomes in the longer two-to-four-year studies.

Bottom line.

The first six months on a GLP-1 are dense with symptoms that, in aggregate, follow a known shape. Most acute GI events cluster around dose changes and attenuate by month 5 or 6. Fatigue concentrates in the first four to eight weeks. Hair shedding shows up on a delay, peaks for a few months, and resolves on the standard telogen-effluvium recovery curve. The "3-month stall" is the metabolic adaptation pattern, not the real pharmacological plateau, which sits around week 60 in the trial data.

Reading the timeline as a curve, instead of as a series of unrelated alarms, is what replaces the "is this normal?" anxiety with a sense of where in the journey a given symptom sits. The curve is the trial population's, not any individual's, and the pattern can vary widely. Anything that sits outside the pattern, or persists past its expected window, is the kind of thing the prescribing team will want to know about.

This article is for educational purposes only and is not medical advice. It describes trial-population patterns, not individual predictions. Always consult your healthcare provider about your specific situation. Read our editorial process for how Symptra articles are researched, written, and reviewed.